Literature DB >> 22125662

CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist.

Jianyong Chen1, Gregory T Collins, Beth Levant, James Woods, Jeffrey R Deschamps, Shaomeng Wang.   

Abstract

We have identified several ligands with high binding affinities to the dopamine D3 receptor and excellent selectivity over the D2 and D1 receptors. CJ-1639 (17) binds to the D3 receptor with a K(i) value of 0.50 nM and displays a selectivity of >5,000 times over D2 and D1 receptors in binding assays using dopamine receptors expressed in the native rat brain tissues. CJ-1639 binds to human D3 receptor with a K(i) value of 3.61 nM and displays over >1000-fold selectivity over human D1 and D2 receptors. CJ-1639 is active at 0.01 mg/kg at the dopamine D3 receptor in the rat and only starts to show a modest D2 activity at doses as high as 10 mg/kg. CJ-1639 is the most potent and selective D3 full agonist reported to date.

Entities:  

Year:  2011        PMID: 22125662      PMCID: PMC3224040          DOI: 10.1021/ml200100t

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

1.  NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.

Authors:  J Yuan; X Chen; R Brodbeck; R Primus; J Braun; J W Wasley; A Thurkauf
Journal:  Bioorg Med Chem Lett       Date:  1998-10-06       Impact factor: 2.823

Review 2.  The D3 dopamine receptor: neurobiology and potential clinical relevance.

Authors:  B Levant
Journal:  Pharmacol Rev       Date:  1997-09       Impact factor: 25.468

3.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

Review 4.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 5.  Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.

Authors:  J N Joyce
Journal:  Pharmacol Ther       Date:  2001 May-Jun       Impact factor: 12.310

6.  Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists.

Authors:  D Boulay; R Depoortere; G Perrault; E Borrelli; D J Sanger
Journal:  Neuropharmacology       Date:  1999-09       Impact factor: 5.250

7.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

8.  1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.

Authors:  Fabrizio Micheli; Luca Arista; Giorgio Bonanomi; Frank E Blaney; Simone Braggio; Anna Maria Capelli; Anna Checchia; Federica Damiani; Romano Di-Fabio; Stefano Fontana; Gabriella Gentile; Cristiana Griffante; Dieter Hamprecht; Carla Marchioro; Manolo Mugnaini; Jacqui Piner; Emiliangelo Ratti; Giovanna Tedesco; Luca Tarsi; Silvia Terreni; Angela Worby; Charles R Ashby; Christian Heidbreder
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

9.  Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

Authors:  Gregor J Macdonald; Clive L Branch; Michael S Hadley; Christopher N Johnson; David J Nash; Alexander B Smith; Geoffrey Stemp; Kevin M Thewlis; Antonio K K Vong; Nigel E Austin; Phillip Jeffrey; Kim Y Winborn; Izzy Boyfield; Jim J Hagan; Derek N Middlemiss; Charlie Reavill; Graham J Riley; Jeannette M Watson; Martyn Wood; Steve G Parker; Charles R Ashby
Journal:  J Med Chem       Date:  2003-11-06       Impact factor: 7.446

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  9 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

2.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

3.  Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability.

Authors:  Jianyong Chen; Cheng Jiang; Beth Levant; Xiaoqin Li; Ting Zhao; Bo Wen; Ruijuan Luo; Duxin Sun; Shaomeng Wang
Journal:  ChemMedChem       Date:  2014-10-22       Impact factor: 3.466

Review 4.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

5.  The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.

Authors:  Francisco O Battiti; Sophie L Cemaj; Adrian M Guerrero; Anver Basha Shaik; Jenny Lam; Rana Rais; Barbara S Slusher; Jeffery R Deschamps; Greg H Imler; Amy Hauck Newman; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-07-01       Impact factor: 7.446

Review 6.  Reactions of Allylmagnesium Reagents with Carbonyl Compounds and Compounds with C═N Double Bonds: Their Diastereoselectivities Generally Cannot Be Analyzed Using the Felkin-Anh and Chelation-Control Models.

Authors:  Nicole D Bartolo; Jacquelyne A Read; Elizabeth M Valentín; K A Woerpel
Journal:  Chem Rev       Date:  2020-01-06       Impact factor: 60.622

7.  Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists.

Authors:  Jianyong Chen; Beth Levant; Cheng Jiang; Thomas M Keck; Amy Hauck Newman; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

Review 8.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

9.  Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Authors:  Mu-Fa Zou; Thomas M Keck; Vivek Kumar; Prashant Donthamsetti; Mayako Michino; Caitlin Burzynski; Catherine Schweppe; Alessandro Bonifazi; R Benjamin Free; David R Sibley; Aaron Janowsky; Lei Shi; Jonathan A Javitch; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-04-01       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.